Bristol Myers Squibb Co. has identified triazole N-linked carbamoyl cyclohexyl acids acting as lysophosphatidic acid LPA1 receptor (LPAR1; EDG2) antagonists reported to be useful for the treatment of fibrosis, cancer, transplant rejection, osteoporosis, inflammatory disorders, neuropathic pain, atherosclerosis and chronic obstructive pulmonary disease, among others.